Article: Therapeutic effect of hepatitis B surface antigen-antibody complex is associated with cytolytic and non-cytolytic immune responses in hepatitis B patients

File Download Links for fulltext
(May Require Subscription)
Supplementary
  • Basic View
  • Metadata View
  • XML View
TitleTherapeutic effect of hepatitis B surface antigen-antibody complex is associated with cytolytic and non-cytolytic immune responses in hepatitis B patients
AuthorsYao, X4
Zheng, B3
Zhou, J3
Xu, DZ1
Zhao, K2
Sun, SH4
Yuan, ZH4
Wen, YM4
Issue Date2007
PublisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccine
CitationVaccine, 2007, v. 25 n. 10, p. 1771-1779 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.vaccine.2006.11.019
AbstractTo study the responses of chronic hepatitis B patients to yeast-derived HBsAg-HBIG complexes (YIC) and the mechanisms involved, twenty HBeAg-positive chronic hepatitis B patients were immunized with 60 μg of YIC or alum as the control at 4-week intervals, for 24 weeks. Five of ten patients responded to 60 μg YIC immunization showing ≥2 logs decrease of serum HBV DNA with loss or marked reduction of HBeAg and appearance of anti-HBe; two of these patients developed anti-HBs. Flares of alanine aminotransferase were observed in 4 of the 5 responders, and in 2 out of 10 control patients. HBsAg-stimulated peripheral blood mononuclear cells (PBMCs) secreted Th1/Th2 cytokines around 24 weeks after immunization. Dendritic cells incubated with YIC showed the highest levels of IL-12 secretion and up-regulation of functional markers. Thus, the therapeutic effect of YIC is associated with cytolytic and non-cytolytic responses in patients. © 2006 Elsevier Ltd. All rights reserved.
ISSN0264-410X
2011 Impact Factor: 3.766
2011 SCImago Journal Rankings: 0.369
DOIhttp://dx.doi.org/10.1016/j.vaccine.2006.11.019
ISI Accession Number IDWOS:000244642700009
ReferencesReferences in Scopus
DC Field
Value
dc.contributor.authorYao, X
dc.contributor.authorZheng, B
dc.contributor.authorZhou, J
dc.contributor.authorXu, DZ
dc.contributor.authorZhao, K
dc.contributor.authorSun, SH
dc.contributor.authorYuan, ZH
dc.contributor.authorWen, YM
dc.date.accessioned2012-08-08T08:50:14Z
dc.date.available2012-08-08T08:50:14Z
dc.date.issued2007
dc.description.abstractTo study the responses of chronic hepatitis B patients to yeast-derived HBsAg-HBIG complexes (YIC) and the mechanisms involved, twenty HBeAg-positive chronic hepatitis B patients were immunized with 60 μg of YIC or alum as the control at 4-week intervals, for 24 weeks. Five of ten patients responded to 60 μg YIC immunization showing ≥2 logs decrease of serum HBV DNA with loss or marked reduction of HBeAg and appearance of anti-HBe; two of these patients developed anti-HBs. Flares of alanine aminotransferase were observed in 4 of the 5 responders, and in 2 out of 10 control patients. HBsAg-stimulated peripheral blood mononuclear cells (PBMCs) secreted Th1/Th2 cytokines around 24 weeks after immunization. Dendritic cells incubated with YIC showed the highest levels of IL-12 secretion and up-regulation of functional markers. Thus, the therapeutic effect of YIC is associated with cytolytic and non-cytolytic responses in patients. © 2006 Elsevier Ltd. All rights reserved.
dc.description.natureLink_to_subscribed_fulltext
dc.identifier.citationVaccine, 2007, v. 25 n. 10, p. 1771-1779 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.vaccine.2006.11.019
dc.identifier.doihttp://dx.doi.org/10.1016/j.vaccine.2006.11.019
dc.identifier.epage1779
dc.identifier.isiWOS:000244642700009
dc.identifier.issn0264-410X
2011 Impact Factor: 3.766
2011 SCImago Journal Rankings: 0.369
dc.identifier.issue10
dc.identifier.pmid17224217
dc.identifier.scopuseid_2-s2.0-33846650945
dc.identifier.spage1771
dc.identifier.urihttp://hdl.handle.net/10722/157471
dc.identifier.volume25
dc.languageeng
dc.publisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccine
dc.publisher.placeUnited Kingdom
dc.relation.ispartofVaccine
dc.relation.referencesReferences in Scopus
dc.subject.meshAdolescent
dc.subject.meshAdult
dc.subject.meshAlanine Transaminase - Blood
dc.subject.meshAntigen-Antibody Complex - Immunology - Therapeutic Use
dc.subject.meshCytokines - Biosynthesis
dc.subject.meshDna, Viral - Blood
dc.subject.meshDendritic Cells - Immunology
dc.subject.meshHepatitis B Antibodies - Blood - Immunology
dc.subject.meshHepatitis B Surface Antigens - Immunology
dc.subject.meshHepatitis B E Antigens - Blood
dc.subject.meshHepatitis B, Chronic - Immunology - Therapy
dc.subject.meshHumans
dc.subject.meshLeukocytes, Mononuclear - Immunology
dc.subject.meshMiddle Aged
dc.titleTherapeutic effect of hepatitis B surface antigen-antibody complex is associated with cytolytic and non-cytolytic immune responses in hepatitis B patients
dc.typeArticle
Author Affiliations
  1. Beijing Ditan Hospital
  2. Beijing Tiantan Biological Products Co. Ltd.
  3. The University of Hong Kong
  4. Ministry of Health of People's Republic of China